-2%
Ninacent is prescribed for adults in the treatment of:
- Idiopathic Pulmonary Fibrosis (IPF)
- Chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype
- Systemic sclerosis-associated interstitial lung disease (SSc-ILD)
Locally advanced, metastatic, or recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma histology, in combination with docetaxel, following first-line chemotherapy
Nintedanib is a multi-targeted tyrosine kinase inhibitor that blocks the activity of several receptor and non-receptor tyrosine kinases implicated in fibrosis and tumor progression.
It competitively inhibits receptors such as:
PDGFR-α/β (platelet-derived growth factor receptors)
FGFR 1–3 (fibroblast growth factor receptors)
VEGFR (vascular endothelial growth factor receptors)
FLT3, Lck, Lyn, and Src
By binding to the ATP-binding sites of these receptors, Nintedanib disrupts downstream pathways responsible for:
Fibroblast proliferation and migration
Angiogenesis in tumors
Progression of pulmonary fibrosis
